Barclays
TBIO

Barclays’s Telesis Bio, Inc. Common Stock TBIO Stock Holding History

Barclays’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27
Closed -$504 – 5387
2023
Q3 		$504 Hold
27
– – ﹤0.01% 4510
2023
Q2 		$766 Sell
27
-99
-79% -$3.95K ﹤0.01% 4374
2023
Q1 		$7.05K Hold
126
– – ﹤0.01% 4786
2022
Q4 		$2.73K Hold
126
– – ﹤0.01% 5063
2022
Q3 		$4K Sell
126
-569
-82% -$20K ﹤0.01% 4551
2022
Q2 		$23K Sell
695
-390
-36% -$26.9K ﹤0.01% 4344
2022
Q1 		$105K Buy
+1,085
New +$165K ﹤0.01% 3759

Other funds holding TBIO

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Barclays's TBIO Position: Q4 2023 in Review

Barclays sold out of Telesis Bio, Inc. Common Stock (TBIO) in Q4 2023, closing a stake of 27 shares — an estimated $504 sold.

Barclays first reported a position in TBIO in Q1 2022 and held it in 7 quarters. The position peaked at $105K in Q1 2022. 24 funds tracked by Wall St. Rank hold TBIO as of Q4 2023.

  • Barclays reported no remaining Telesis Bio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Barclays sold 27 Telesis Bio, Inc. Common Stock shares in Q4 2023, an estimated $504.
  • Barclays first reported a position in Telesis Bio, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
  • Barclays's Telesis Bio, Inc. Common Stock position peaked at $105K in Q1 2022.
  • 24 funds tracked by Wall St. Rank held Telesis Bio, Inc. Common Stock as of Q4 2023.

Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.